Literature DB >> 6271423

Serum apoprotein A-I and A-II levels in liver diseases and cholestasis.

S Fujii, S Koga, T Shono, K Yamamoto, H Ibayashi.   

Abstract

Serum apoprotein A-I and A-II levels were determined by electroimmunoassay in patients with liver diseases and cholestasis. Significant decreases in apoprotein A-I and A-II levels were observed in such patients. The decreases were especially pronounced in the early phase of acute hepatitis and cholestasis. The decreases in A-II levels were more prominent than the decreases in A-I in severe hepatic dysfunction or cholestasis. Accordingly, the A-I/A-II ratio showed no change in the convalescent phase of acute hepatitis or chronic hepatitis but increased significantly in the early phase of acute hepatitis, cirrhosis of the liver, hepatoma, and cholestasis. The results suggested the existence of a high density lipoprotein with an abnormal apoprotein composition or a more profound decrease of HDL3 than of HDL2 in severe hepatocellular dysfunction of cholestasis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271423     DOI: 10.1016/0009-8981(81)90245-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Alterations in levels of apolipoprotein C-III and C-II/C-III ratios in patients with liver disease.

Authors:  S Koga; K Yamamoto; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1984-02

2.  Quantitative determinations of HDL2 and HDL3 in patients with liver disease.

Authors:  S Koga; T Shono; M Inoue; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1983-02

3.  Increased proportion of proapolipoprotein A-I in HDL from patients with liver cirrhosis and hepatitis.

Authors:  T Matsuura; S Koga; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1988-08

4.  Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells.

Authors:  Pamela A Norton; Qiaoke Gong; Anand S Mehta; Xuanyong Lu; Timothy M Block
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Role of Lipids and Apolipoproteins in Predicting the Prognosis of Hepatocellular Carcinoma After Resection.

Authors:  Xiao-Chun Ni; Yong Yi; Yi-Peng Fu; Xiao-Yan Cai; Gao Liu; Jin-Long Huang; Wei Gan; Jie Xu; Shuang-Jian Qiu
Journal:  Onco Targets Ther       Date:  2020-12-16       Impact factor: 4.147

6.  Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases.

Authors:  Jingting Jiang; Xiaoying Zhang; Changping Wu; Xihu Qin; Guanghua Luo; Haifeng Deng; Minyang Lu; Bin Xu; Min Li; Mei Ji; Ning Xu
Journal:  Lipids Health Dis       Date:  2008-07-24       Impact factor: 3.876

Review 7.  Influence of liver cancer on lipid and lipoprotein metabolism.

Authors:  Jingting Jiang; Peter Nilsson-Ehle; Ning Xu
Journal:  Lipids Health Dis       Date:  2006-03-03       Impact factor: 3.876

8.  DNA and RNA Sequencing Recapitulated Aberrant Tumor Metabolism in Liver Cancer Cell Lines.

Authors:  Yihong Sun; Xia Tang; Bo Ye; Keyue Ding
Journal:  J Hepatocell Carcinoma       Date:  2021-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.